ArticleJournal of molecular histology2026
LncRNA MNX1-AS1 drives the progression of non-small cell lung cancer and serves as a ceRNA to target COMMD8 by sponging miR-218-5p.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role and mechanistic action of MNX1-AS1 in non-small cell lung cancer (NSCLC) remain unclear. This study aimed to investigate the function of MNX1-AS1 in the progression of NSCLC. A total of 40 paired tumor and adjacent lung tissue samples from patients with NSCLC were collected to investigate the expression of MNX1-AS1. H1299 and HCC827 cells were transfected with sh-MNX1-AS1, shRNA-NC, miR-218-5p mimic, mimic-NC, pcDNA3.1-COMMD8, or empty vector (pcDNA3.1). The expression of MNX1-AS1, miR-218-5p, and COMMD8 was detected using quantitative real-time PCR (qRT-PCR). Cell proliferation was evaluated using CCK-8 assays, while cell migration and invasion were evaluated using Transwell assays. Dual-luciferase reporter and RNA pull-down assays were performed to validate the targeting interactions between MNX1-AS1 and miR-218-5p, as well as between COMMD8 and miR-218-5p. In vivo, a nude mouse model was established: tumor volume and weight were measured after four weeks. Gene expression in tumor tissue was quantified using qRT-PCR, and Ki-67 expression was evaluated using immunohistochemistry. MNX1-AS1 expression was significantly upregulated in NSCLC tissues (P < 0.05) and was correlated with poor prognosis in NSCLC patients. MNX1-AS1 knockdown markedly suppressed the viability, migration, and invasion of H1299 and HCC827 cells (P < 0.05). Mechanistically, MNX1-AS1 acted as a molecular sponge for miR-218-5p, thereby relieving miR-218-5p-mediated repression of its direct target COMMD8 (P < 0.05). Functional rescue experiments revealed that miR-218-5p silencing or COMMD8 overexpression partially reversed the inhibitory effects of MNX1-AS1 knockdown on the cell viability, migration, and invasion of H1299 and HCC827 cells. In vivo, sh-MNX1-AS1 significantly reduced tumor volume and weight (P < 0.05). Moreover, the expression of MNX1-AS1, COMMD8, and Ki-67 were downregulated, while the expression of miR-218-5p was upregulated in sh-MNX1-AS1 tumor tissues (P < 0.05). MNX1-AS1 promotes the progression of NSCLC by modulating the miR-218-5p/COMMD8 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.